| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2011: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2010: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2009: ¥8,970,000 (Direct Cost: ¥6,900,000、Indirect Cost: ¥2,070,000)
|
|---|
| Research Abstract |
Many features of adipose stem/progenitor cells, such as physiological functions and localization, have been clarified in the past decade. Adipose tissue turns over very slowly and its perivascular progenitor cells differentiate into new adipocytes, replacing dead adipocytes. A number of clinical trials using freshly isolated or cultured adipose-derived stromal cells(ASCs) containing adipose progenitor/stem cells are ongoing in more than ten countries. Therapeutic use of adipose stem/progenitor cells has been shown to promote angiogenesis and adipose tissue regeneration. Identification of adipocyte releasing factors upon apoptosis/necrosis would be a break-through to step up to the next stage for adipose tissue regeneration. Activation of precursors in perichondrium and periosteum shows a dramatic neogenesis by only a simple injection and an ideal example of in situ tissue engineering. The "hit and catch" strategy using a mobilizer of bone-marrow stem/progenitor cells and a catcher(attractants) to lead the cells to proper homing into the target tissue may be our future direction of promote manipulation of stem cells. Careful design of microenvironment activating ASCs, cell delivery protocol to avoid unexpected behavior and induce maximal potential of ASCs, and selection of target diseases, will be critical to the success of clinical applications.
|
